RATIONALE: Acute administration of serotonergic agonist, meta-chlorophenylpiperazine (mCPP), attenuates performance of compulsive checking in an animal model of obsessive-compulsive disorder (OCD). It is not known whether mCPP has a similar effect on development of compulsive checking. OBJECTIVES: The objective of the study was to examine whether similar mechanisms mediate the development versus the performance of compulsive checking in the rat model. METHODS: Four groups of male rats (N = 14/group) were tested: two experimental groups co-injected with D2/D3 dopamine agonist quinpirole (0.25 mg/kg) and mCPP (0.625 mg/kg or 1.25 mg/kg), and two control groups, one co-injected with quinpirole and saline, the other receiving injections of saline. The time course of development of compulsive checking across injections 1 to 10 in quinpirole-treated rats was compared to rats co-injected with quinpirole and mCPP. RESULTS: Results showed that during the course of chronic treatment, mCPP (1.25 mg/kg) significantly attenuated performance of checking behavior. However, when these rats were retested for expression of compulsive checking (that is, with an injection of quinpirole only), their profile of compulsive checking was no different from the control rats treated throughout with quinpirole only. CONCLUSIONS: Findings show that mCPP inhibits performance of compulsive checking but does not block quinpirole from inducing the neural substrate underlying this compulsive behavior. Hence, a separate mechanism underlies the induction of compulsive checking and the performance of it. It is suggested that development of the OCD endophenotype reflects neuroplastic changes produced by repeated dopamine D2/D3 receptor stimulation, while stimulation of serotonergic receptors mediates a negative feedback signal that shuts down the motor performance of checking.
RATIONALE: Acute administration of serotonergic agonist, meta-chlorophenylpiperazine (mCPP), attenuates performance of compulsive checking in an animal model of obsessive-compulsive disorder (OCD). It is not known whether mCPP has a similar effect on development of compulsive checking. OBJECTIVES: The objective of the study was to examine whether similar mechanisms mediate the development versus the performance of compulsive checking in the rat model. METHODS: Four groups of male rats (N = 14/group) were tested: two experimental groups co-injected with D2/D3 dopamine agonist quinpirole (0.25 mg/kg) and mCPP (0.625 mg/kg or 1.25 mg/kg), and two control groups, one co-injected with quinpirole and saline, the other receiving injections of saline. The time course of development of compulsive checking across injections 1 to 10 in quinpirole-treated rats was compared to rats co-injected with quinpirole and mCPP. RESULTS: Results showed that during the course of chronic treatment, mCPP (1.25 mg/kg) significantly attenuated performance of checking behavior. However, when these rats were retested for expression of compulsive checking (that is, with an injection of quinpirole only), their profile of compulsive checking was no different from the control rats treated throughout with quinpirole only. CONCLUSIONS: Findings show that mCPP inhibits performance of compulsive checking but does not block quinpirole from inducing the neural substrate underlying this compulsive behavior. Hence, a separate mechanism underlies the induction of compulsive checking and the performance of it. It is suggested that development of the OCD endophenotype reflects neuroplastic changes produced by repeated dopamine D2/D3 receptor stimulation, while stimulation of serotonergic receptors mediates a negative feedback signal that shuts down the motor performance of checking.
Authors: J R Martin; M Bös; F Jenck; J Moreau; V Mutel; A J Sleight; J Wichmann; J S Andrews; H H Berendsen; C L Broekkamp; G S Ruigt; C Köhler; A M Delft Journal: J Pharmacol Exp Ther Date: 1998-08 Impact factor: 4.030
Authors: E Hollander; C DeCaria; R Gully; A Nitescu; R F Suckow; J M Gorman; D F Klein; M R Liebowitz Journal: Psychiatry Res Date: 1991-01 Impact factor: 3.222
Authors: W K Goodman; C J McDougle; L H Price; L C Barr; O F Hills; J F Caplik; D S Charney; G R Heninger Journal: Biol Psychiatry Date: 1995-08-01 Impact factor: 13.382
Authors: Henry Szechtman; Susanne E Ahmari; Richard J Beninger; David Eilam; Brian H Harvey; Henriette Edemann-Callesen; Christine Winter Journal: Neurosci Biobehav Rev Date: 2016-05-07 Impact factor: 8.989
Authors: Milou Straathof; Erwin L A Blezer; Christel E Smeele; Caroline van Heijningen; Annette van der Toorn; Jan K Buitelaar; Jeffrey C Glennon; Willem M Otte; Rick M Dijkhuizen Journal: Psychopharmacology (Berl) Date: 2022-04-14 Impact factor: 4.415
Authors: Javier Ballester González; Anna Dvorkin-Gheva; Charmaine Silva; Jane A Foster; Henry Szechtman Journal: Behav Pharmacol Date: 2015-02 Impact factor: 2.293
Authors: D M Eagle; C Schepisi; S Chugh; S Desai; S Y S Han; T Huang; J J Lee; C Sobala; W Ye; A L Milton; T W Robbins Journal: Psychopharmacology (Berl) Date: 2020-09-04 Impact factor: 4.530
Authors: Mark C Tucci; Anna Dvorkin-Gheva; Eric Johnson; Paul Cheon; Leena Taji; Arnav Agarwal; Jane Foster; Henry Szechtman Journal: Eur J Neurosci Date: 2014-06-16 Impact factor: 3.386
Authors: Mélanie Lagière; Marion Bosc; Sara Whitestone; Abdelhamid Benazzouz; Abdeslam Chagraoui; Mark J Millan; Philippe De Deurwaerdère Journal: Int J Mol Sci Date: 2020-11-12 Impact factor: 5.923